1 Pollard S, Nashan B, Johnston A, Hoyer P, Belitsky P, Keown P, et al.pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A[J].Clin Ther, 2003;25:1654-69 2 吴闯, 邓耀良, 李如栋, 陈君祯.国产环孢素胶丸的相对生物利用度研究 [J].中国药房, 2002;13:249-50 3 Feutren G.The optimal use of cyclosporin A in autoimmune diseases [J].J Autoimmun, 1992;5:183-95 4 Meier-Kriesche HU, Swinford R, Kahan BD, Brannan P, Portman RJ.Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation [J].Pediatr Nephrol, 2000;15: 2-6 5 Wong SH.Therapeutic drug monitoring for immunosuppressants [J].Clin Chim Acta, 2001;313:241-53 6 del Mar Fernandez, De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ.Immunosuppressive therapy for paediatric transplant patients:pharmacokinetic considerations [J].Clin Pharmacokinet, 2002;4:115-35 7 Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, et al.Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)[J].Transplantation, 2002;73:953-9 8 Yoshida K, Kimura T, Hamada Y, Saito T, Endo T, Baba S. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from Sandimmune to Neoral in stable renal transplant patients[J].Transplant Proc, 2001;33: 3146-7 9 Hricik DE, Dixit A, Knauss TC, Donley V, Bartucci MR, Schulak JA.Benefits of pre-emptive dose reduction for Sandimmune to Neoral conversion in stable renal transplant recipients [J].Clin Transplant, 1998;12:575-8 |